What is HC Wainwright’s Forecast for WVE Q1 Earnings?

Wave Life Sciences Ltd. (NASDAQ:WVE) – HC Wainwright issued their Q1 2025 earnings estimates for Wave Life Sciences in a research note issued to investors on Wednesday, March 5th. HC Wainwright analyst A. Fein anticipates that the company will earn ($0.26) per share for the quarter. HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for Wave Life Sciences’ Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.22) EPS and Q4 2025 earnings at ($0.15) EPS.

Wave Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.34. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. The business had revenue of $83.75 million for the quarter, compared to analyst estimates of $25.60 million.

A number of other equities research analysts have also commented on WVE. StockNews.com upgraded shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Thursday, February 27th. Truist Financial lifted their price objective on shares of Wave Life Sciences from $17.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, November 12th. Mizuho raised their target price on shares of Wave Life Sciences from $19.00 to $22.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Finally, Jefferies Financial Group started coverage on shares of Wave Life Sciences in a research note on Tuesday, February 25th. They set a “buy” rating and a $26.00 target price for the company. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.60.

Wave Life Sciences Stock Performance

WVE opened at $9.40 on Thursday. The firm’s fifty day moving average is $11.44 and its two-hundred day moving average is $11.21. The firm has a market cap of $1.43 billion, a PE ratio of -8.47 and a beta of -1.09. Wave Life Sciences has a twelve month low of $4.25 and a twelve month high of $16.74.

Insiders Place Their Bets

In other news, CEO Paul Bolno sold 169,025 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the completion of the sale, the chief executive officer now owns 338,351 shares of the company’s stock, valued at approximately $3,238,019.07. This represents a 33.31 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 29.10% of the company’s stock.

Institutional Trading of Wave Life Sciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its holdings in shares of Wave Life Sciences by 209.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 844,617 shares of the company’s stock worth $6,926,000 after acquiring an additional 571,345 shares during the period. FMR LLC lifted its holdings in shares of Wave Life Sciences by 174.5% during the 3rd quarter. FMR LLC now owns 1,540,190 shares of the company’s stock worth $12,630,000 after acquiring an additional 979,110 shares during the period. Maven Securities LTD bought a new stake in shares of Wave Life Sciences during the 3rd quarter worth approximately $6,970,000. Privium Fund Management B.V. bought a new stake in shares of Wave Life Sciences during the 3rd quarter worth approximately $400,000. Finally, Barclays PLC lifted its holdings in shares of Wave Life Sciences by 171.1% during the 3rd quarter. Barclays PLC now owns 159,241 shares of the company’s stock worth $1,307,000 after acquiring an additional 100,498 shares during the period. Institutional investors own 89.73% of the company’s stock.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.